AB-3PRGD2
AB-3PRGD2 is a radiotherapeutic agent targeting integrin αvβ3. AB-3PRGD2 shows improved tumor uptake and prolonged tumor retention, leading to significantly enhanced tumor growth suppression. AB-3PRGD2 can remodel the tumor immune microenvironment by upregulating PD-L1 expression and increasing tumor-infiltrating CD8+ T cells[1].
Product Specifications
CAS Number
2416165-76-7
UNSPSC
12352005
Target
Integrin; PD-1/PD-L1
Related Pathways
Cytoskeleton; Immunology/Inflammation
Field of Research
Cancer
Smiles
OC(CN(CCN(CCN(CC1)CC(O)=O)CC(O)=O)CCN1CC(N[C@H](C(N[C@@H](C(O)=O)CCCCNC(CCCC2=CC=C(C=C2)I)=O)=O)CSC3C(N(C(C3)=O)CCCCCC(NCCOCCOCCOCCOCCC(N[C@H](C(NCCOCCOCCOCCOCCC(NCCCC[C@@H]4NC([C@H](NC([C@@H](NC(CNC([C@@H](NC4=O)CCCNC(N)=N)=O)=O)CC(O)=O)=O)CC5=CC=CC=C5)=O)=O)=O)CCC(NCCOCCOCCOCCOCCC(NCCCC[C@@H]6NC([C@H](NC([C@@H](NC(CNC([C@@H](NC6=O)CCCNC(N)=N)=O)=O)CC(O)=O)=O)CC7=CC=CC=C7)=O)=O)=O)=O)=O)=O)=O)=O
Molecular Formula
C137H215IN30O45S
Molecular Weight
3161.32
References & Citations
[1]Shi J, et al. Nuclear imaging of PD-L1 expression promotes the synergistic antitumor efficacy of targeted radionuclide therapy and immune checkpoint blockade. Eur J Nucl Med Mol Imaging. 2025 Feb;52 (3) :955-969.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
MBS1411167-01 0.02 mg (E-Coli)
Recombinant Helicobacter pylori Dihydroorotase (pyrC)
Sign In for Pricing
View Details MBS1411167-02 0.02 mg (Yeast)
Recombinant Helicobacter pylori Dihydroorotase (pyrC)
Sign In for Pricing
View Details MBS1411167-03 0.1 mg (E-Coli)
Recombinant Helicobacter pylori Dihydroorotase (pyrC)
Sign In for Pricing
View Details MBS1411167-04 0.1 mg (Yeast)
Recombinant Helicobacter pylori Dihydroorotase (pyrC)
Sign In for Pricing
View Details